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Background: HIV-1 viral infectivity factor (Vif) is an essential accessory protein for HIV-1 replication. The predominant
function of Vif is to counteract Apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G, A3G),
a potent host restriction factor that inhibits HIV-1 replication. Vif mediates the proteasomal degradation of A3G
and inhibits A3G translation, thus diminishing the pool of A3G that is available to be packaged into budding virion.
Although Vif is robust in degrading A3G, the protection provided against A3G is not absolute. Clinical and laboratory
evidence have shown that A3G is not completely excluded from HIV-1 viral particles during HIV-1 replication. It remains
unclear why the viral samples are still infectious when A3G has been packaged into the virions.
Results: In this study, we provide evidence that Vif continues to protect HIV-1 from the deleterious effects of A3G,
even after packaging of A3G has occurred. When equal amounts of A3G were packaged into budding virions, the
virus expressing functional Vif was more infectious and incurred fewer G to A hypermutations in the second round
of infection compared to Vif-deficient virus. A Vif mutant with a defect in viral packaging showed a reduced ability
to protect the HIV-1 genome from G to A hypermutations.
Conclusion: Our data suggest that even packaged A3G is still under the tyranny of Vif. Our work brings to light an
additional caveat for any therapy that hopes to exploit the Vif-A3G axis. The ideal strategy would not only enhance
A3G viral packaging, but also reduce HIV-1 Vif viral encapsidation.
Keywords: HIV-1, Vif, APOBEC3G, Hypermutation, Cytidine deaminaseBackground
Apolipoprotein B mRNA-editing enzyme-catalytic
polypeptide-like 3G (APOBEC3G, A3G) is a member of
the APOBEC3 family of cytidine deaminases, which in-
cludes A3A, B, C, D/E and F, with A3G being the most po-
tent against HIV-1 [1]. In the absence of Vif, A3G will
encapsidate into HIV-1 virions and induce G to A hyper-
mutations in the newly synthesized viral DNA [2-6]. A3G
also exerts inhibitory effects at several other steps of HIV-
1 replication, such as reverse transcription and viral DNA
integration [1].
HIV-1 Vif is a 23 kDa accessory protein of HIV-1. The
critical role of Vif in HIV-1 infectivity was observed* Correspondence: bliu@mmc.edu
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unless otherwise stated.shortly after the discovery of HIV-1 [7,8]; however, the
mechanism by which Vif protects the integrity of HIV-1
took over a decade to decode. Seminal work by Sheehy
et al. led to the discovery that the predominant function
of Vif is to counteract A3G [9]. The general consensus is
that Vif orchestrates proteasomal degradation of A3G,
thus preventing its packaging into the budding virion
[10-16]. During this process, HIV-1 Vif interacts with
Cullin 5, A3G and the newly identified T cell differenti-
ation factor, CBfβ, to promote formation of the Cullin 5-
Vif- A3G ubiquitin E3 ligase complex, which marks A3G
for proteasomal degradation [16-21]. While Vif-mediated
degradation of A3G is the well-recognized mechanism by
which Vif rescues HIV-1, it has also been proposed that
Vif prevents A3G viral packaging through inhibiting A3G
translation [15,22] or another unknown mechanism [23].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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shown that Vif has the capability of directly inhibiting
A3G cytidine deaminase activity in a degradation-
independent manner. Santa-Marta et al. showed that
A3G-induced cytidine deamination is inhibited by the
expression of Vif, without the depletion of a deaminase
domain, in an Escherichia coli system. Moreover, inhib-
ition of deaminase-mediated bacterial hypermutation is
dependent on a single amino acid substitution D128K
that renders A3G resistant to Vif inhibition [24]. Britan-
Rosich et al. also showed that Vif is able to inhibit A3G
cytidine deaminase activity in vitro [25]. Recently, Feng
et al. reported that HIV-1 Vif alters processive single-
stranded DNA scanning of A3G in vitro [26]. However,
it remains unclear if the inhibitory effect of Vif on A3G
cytidine deaminase activity is integral for successful
HIV-1 replication following Vif-A3G encapsidation into
progeny virions. In this study, we provide evidence that
Vif continues to protect HIV-1 from the deleterious ef-
fects of A3G even after packaging of A3G has occurred.
When equal amounts of A3G were packaged into bud-
ding virions with functional or non-functional Vif, the
virus expressing functional Vif was more infectious, and
fewer G to A hypermutations were generated in the sec-
ond round of infection compared to virions without
functional Vif. Our work indicates that Vif plays an add-
itional role in protecting HIV-1 from A3G after encapsi-
dation. This work sheds light on the fact that any therapy
that hopes to exploit the Vif-A3G axis needs to take into
account that even though A3G becomes packaged, Vif is
still able to maintain the fidelity of the virus.
Results
Antiviral activity of A3G is less potent against wild-type
virus compared to Vif-deficient virus
HIV-1 Vif counteracts A3G antiviral function by mediat-
ing its degradation, which leads to the exclusion of A3G
from budding viral particles. However, a previous study
has shown that residual amounts of A3G still exists in
Vif-competent wild-type HIV-1 particles [27]. To study
the antiviral function of the residual amount of A3G
found in progeny virions, different amount of A3G were
cotransfected with HXB2N into 293T cells. Concur-
rently, A3G was cotransfected with HXB2NΔVif into
293T cells. Culture supernatants were harvested from
the transfected cells 48 h after transfection. The samples
were purified by ultracentrifugation and subjected to
MAGI assay and Western blot analysis for measuring
viral infectivity and A3G expression levels in progeny vi-
rions, respectively. As shown in Figure 1, the amount of
A3G in the virion from 20 μg A3G/HXB2N sample was
more than 4 μg A3G/HXB2NΔVif sample (169% vs
100%). However, the infectivity of the former virus was
much higher than the one of 4 μg A3G/HXB2NΔVifsample (Figure 1 lane 5 vs lane 7). These data suggest
that wild-type HIV-1 circumvents A3G antiviral function
more efficiently than Vif-deficient virus, and thus Vif
may have an additional ability to overcome A3G even
after A3G has been packaged into viral particles.
HIV-1 Vif inhibits A3G cytidine deaminase activity in both
cells and virion
In our previous report, we demonstrated that a
hemagglutinin (HA) tag fused to the N terminus of
lysine-free A3G (HAA3G22K) renders HAA3G22K re-
sistant to Vif-induced degradation [28]. HAA3G22K is
equally packaged into wild-type and Vif-deficient HIV-1
virions. Therefore, HAA3G22K is an optimal mutant to
characterize the antiviral function of A3G in the pres-
ence of HIV-1 Vif. To that end, HXB2N, HXB2NΔVif or
HXB2B3 was cotransfected into 293T cells with HA
A3G22K or A3GD128K. HXB2B3 contains three point
mutations in the C-terminal region of Vif as described
in the Methods section. Cells and culture supernatants
were harvested 48 h post-transfection, and viral particles
were isolated from the culture supernatants by ultracen-
trifugation. Cells and viral samples were subjected to the
A3G cytidine deaminase assay. When Vif (Figure 2B,
HXB2N) or VifB3 (Figure 2B, HXB2B3) were co-expressed
with HAA3G22K in 293T cells, the cytidine deaminase
activity of HAA3G22K decreased by 50% compared
to Vif-deficient virus (Figure 2B, HXB2NΔVif ). Even
though HAA3G22K was packaged equally into the three
different virions (Figure 2A), the cytidine deaminase
activity of HAA3G22K was lower by 3- and 2-fold in
HXB2N and HXB2B3, respectively, compared to HX-
B2NΔVif (Figure 2B). These data suggest that Vif in-
hibits HAA3G22K cytidine deaminase activity not only
in the cells, but also in the virions. When A3GD128K
was used instead of HAA3G22K, there was no differ-
ence in A3GD128K cytidine deaminase activity among
all three viral constructs in both the cells and virions
(Figure 2C). As it has been shown that the Vif-A3G
interplay is blocked when the 128 lysine residue in A3G
is mutated to aspartic acid [29-31], this result (Figure 2C)
suggests that the Vif-A3G interaction is essential for Vif to
inhibit A3G cytidine deaminase activity.
HIV-1 Vif reduces the G to A hypermutation rate
catalyzed by A3G
With the knowledge that Vif inhibits A3G cytidine de-
aminase activity in both cells and virions (Figure 2), we
set out to determine if Vif interferes with the G to A
hypermutation rate catalyzed by A3G. The HIV-1 pro-
viral constructs HXB2N, HXB2NΔVif or HXB2B3 were
cotransfected into 293T cells with A3G, HAA3G22K or
A3GD128K. Culture supernatants were harvested 48 h
post-transfection to determine the infectivity of progeny
Figure 1 A3G antiviral activity is circumvented more efficiently with HXB2N compared to HXB2NΔVif. 4 μg HXB2N or HXB2NΔVif proviral
construct DNA was cotransfected with indicated amount of A3G expression vector DNA into 293T cells. 4 μg pcDNA3.1 was also cotransfected
with HXB2N or HXB2NΔVif into 293T cells as controls. At 48 h after transfection, cell culture supernatants were harvested and used to infect
TZM-bl indicator cells to measure viral infectivity (upper panel). The concentration of viral input was normalized by p24 ELISA. Virions in cell
culture supernatants were precipitated by ultracentrifugation for Western blot analysis (lower panel). The percentage represents the quantity of
intraviral A3G normalized by the quantity of intraviral p24. A3G/HXB2NΔVif was set as 100%. Each experiment in this and subsequent figures was
performed at least three times, and representative results are presented.
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Figure 3A, HXB2B3 retains its capability to degrade
A3G as effectively as wildtype HXB2N. Therefore the in-
fectivity HXB2B3/pcDNA3.1 is similar to HXB2B3/A3G
(Figure 3B). HAA3G22K was equally packaged into HX-
B2N, HXB2NΔVif and HXB2B3 (Figure 3A). Although
HAA3G22K was equally packaged, the infectivity of
HXB2N/HAA3G22K was approximately 10 times higher
than that of HXB2NΔVif/HAA3G22K (Figure 3B). The
infectivity of HXB2B3/HAA3G22K was in the intermedi-
ate range. It is imperative to note that the only differ-
ence among these three viruses is the presence of Vif.
This finding further illustrates that Vif possesses anti-
A3G activity even in progeny virions. The G to A hyper-
mutation rate catalyzed by HXB2N/HAA3G22K wassignificantly lower than that of HXB2NΔVif/HAA3G22K
(Figure 3C), while that of HXB2B3 ranged in between
those values. This result indicates that Vif reduces the G
to A hypermutation rate catalyzed by A3G even after
A3G is packaged into viral particles. Using the A3GD128K
mutant instead of HAA3G22K showed that Vif was un-
able to maintain viral infectivity (Figure 3B), and the rate
of G to A hypermutation (Figure 3C) was constant, further
indicating that Vif requires interaction with A3G to main-
tain viral infectivity.
VifB3 mutant encapsidation into HIV particles is defective
Compared to wild-type Vif, VifB3 is less efficient in inhibit-
ing A3G cytidine deaminase activity in virions (Figure 2B),
reducing G to A hypermutations (Figure 3C) and retaining
Figure 2 HIV-1 Vif destroys A3G cytidine deaminase activity in both cells and virions. 293T cells were cotransfected with HAA3G22K
or A3GD128K in combination with HXB2N, HXB2NΔVif or HXB2B3. At 48 h post-transfection, the cells were collected, and virions in culture
supernatants were precipitated by ultracentrifugation for Western blot analysis (A). HAA3G22K was cotransfected into 293T cells with HXB2N,
HXB2NΔVif or HXB2B3. At 48 h post-transfection, cells and culture supernatants were harvested to measure A3G cytidine deaminase activity (B).
A3GD128K was cotransfected into 293T cells with HXB2N, HXB2NΔVif or HXB2B3. At 48 h post-transfection, cells and culture supernatants were
harvested to measure A3G cytidine deaminase activity (C).
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tion of the HXB2B3 mutant has been reported to be simi-
lar to that of wild-type HIV-1 virus in SupT1 cells.
However, the HXB2B3 mutant virus shows delayed repli-
cation in H9 cells compared to wild-type virus [32]. Unlike
the high levels of A3G found in H9 cells, SupT1 cells ex-
press negligible to no A3G. From these observations, we
considered that the VifB3 mutant may have a defect in
overcoming A3G antiviral activity compared to wild-type
Vif. To test this hypothesis, we transfected HXB2N,
HXB2NΔVif or HXB2B3 with A3G or HAA3G22K into
293T cells. Cells and viral samples were analyzed by West-
ern blot. Both HXB2N and HXB2B3 efficiently induced
the degradation of A3G in cells and excluded A3G from
viral particles (Figure 4A). As expected, HAA3G22K was
resistant to HXB2N- and HXB2B3-induced degradation
(Figure 4A). Surprisingly, the HXB2B3 virus packaged less
Vif compared to wild-type HXB2N virus despite equal ex-
pression levels found in the cells (Figure 4A). Similarresults were also obtained in the absence of A3G or
HAA3G22K, which suggests that VifB3 packaging is inde-
pendent of A3G and HAA3G22K (Figure 4B). Taken to-
gether (Figures 2 and 3), these data show that packaging of
Vif is essential for it to inhibit A3G cytidine deaminase ac-
tivity in virions, reduce the G to A hypermutation rate and
retain HIV-1 infectivity. Less VifB3 than wild-type Vif was
packaged into budding virions, which may explain why the
activity of VifB3 always ranged between that of wild-type
Vif and no Vif (i.e., Vif-deficient virus) (Figures 2 and 3).
Vif retains infectivity but HIV-1 replication is delayed in
HAA3G22K-expressing Jurkat cells
We have shown that Vif partially retains HIV-1 infectivity
even after HAA3G22K was packaged into the budding
virion (Figure 3B). To further explore this phenomenon in
a T cell system, we established Jurkat cell lines stably ex-
pressing A3G or HAA3G22K. Western blot analysis
showed that similar levels of A3G and HAA3G22K were
Figure 3 Vif counteracts the ability of A3G to induce G to A hypermutations. HXB2N, HXB2NΔVif or HXB2B3 was cotransfected with A3G,
HAA3G22K or A3GD128K into 293T cells. At 48 h post-transfection, culture supernatants were harvested, and virus particles were precipitated by
ultracentrifugation for Western blot analysis (A). The cell culture supernatants were also used to infect TZM-bl indicator cells to measure viral
infectivity (B). The cell culture supernatants from panel A were used to infect SupT1 cells for hypermutation analysis (C).
Figure 4 VifB3 mutant encapsidation into HIV particles is defective. 293T cells were cotransfected with A3G or HAA3G22K and a proviral
construct HXB2N, HXB2NΔVif or HXB2B3. At 48 h post-transfection, cells and culture supernatants were harvested, and viral particles were
precipitated by ultracentrifugation for Western blot analysis (A). HXB2N, HXB2NΔVif or HXB2B3 was transfected into 293T cells. At 48 h
post-transfection, cells were collected, and viral particles in culture supernatants were precipitated by ultracentrifugation for Western blot
analysis (B). The percentage represents the quantity of intraviral Vif normalized by the quantity of intraviral p24. HXB2N was set to 100%.
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HXB2NΔVif or HXB2B3 virus was used to infect Jurkat,
Jurkat/A3G and Jurkat/HAA3G22K cell lines. As ex-
pected, all three viruses replicated very well in Jurkat cell
line (Figure 5B), while HXB2NΔVif could not replicate
in the Jurkat/A3G (Figure 5C) and Jurkat/HAA3G22K
(Figure 5D) cell lines. Wild-type HXB2N virus only partially
replicated in the Jurkat/HAA3G22K cell line (Figure 5D)
compared to its replication in Jurkat (Figure 5B) and
Jurkat/A3G (Figure 5C) cell lines. These results indicate
that Vif was able to partially maintain HXB2N viral infect-
ivity even after HAA3G22K was packaged into HXB2N
virions. In addition, the replication of HXB2B3 was de-
termined not to be robust as HXB2N due to reduced
packaging of VifB3.
Discussion
The discovery of A3G as a potent anti-HIV-1 host re-
striction factor has fostered interest in blocking the Vif-
A3G interaction and ultimately inhibiting Vif-mediatedFigure 5 HXB2N virus replicates more efficiently than HXB2NΔVif or H
cells stably expressing A3G or HAA3G22K were analyzed by Western blot (A
Jurkat (B), Jurkat/A3G (C) and Jurkat/HAA3G22K (D) stable cell lines. Viral su
analyzed by p24 ELISA to measure HIV-1 levels.A3G degradation as a potential treatment strategy. Vif
drastically reduces the cellular pool of A3G and conse-
quently prevents A3G from hitch-hiking a ride with the
nucleocapsid of Gag, viral RNA or 7SL RNA into the
budding virion, thus preserving HIV-1 infectivity [33].
Several studies have also shown that Vif prevents A3G
viral packaging through inhibiting A3G translation [15,22]
or other mechanisms [23].
A3G inhibits HIV-1 replication at several steps of the
HIV-1 life cycle, such as reverse transcription and viral
cDNA integration. However, the hallmark of the potent
antiviral phenotype of A3G is found in its ability to in-
duce lethal G to A hypermutations in the viral genome.
A3G has a strong bias towards catalyzing hypermuta-
tions on minus strand DNA 5’ CC or 5’ CCC. These mu-
tations may lead to the introduction of premature stop
codons and/or result in non-infectious or defective pro-
viruses [34]. Although Vif is robust in degrading A3G,
thus maintaining viral infectivity, the protection pro-
vided against A3G is not absolute. This notion is evidentXB2B3 in Jurkat cell lines stably expressing HAA3G22K. Jurkat
). Virus derived from HXB2N, HXB2NΔVif or HXB2B3 was used to infect
pernatants were harvested on days 1, 3, 5 and 7 post-infection and
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mary viruses isolated from AIDS patients [35-38]. The
dominant mutation patterns found among those hyper-
mutations were in the GG to AG context, which sug-
gests that these mutations were induced by A3G. These
findings illustrate that A3G is not completely excluded
from HIV-1 viral particles even in the presence of Vif.
Observations by Gillick et al. suggest that detectable
amounts of A3G are present in wild-type HIV-1 particles
produced from CD4+ T cells during the course of infec-
tion [27]. However, Xu et al. reported that virion in-
corporation of approximately seven A3G molecules is
sufficient to inhibit the replication of Vif-deficient HIV-
1 [39]. The obvious discrepancy is that the primary iso-
lates from viral samples were Vif-competent virus,
whereas the latter study involved Vif-deficient virus.
Taken together, these studies give credence to the argu-
ment that Vif may preserve HIV-1 infectivity even after
A3G has been packaged into the virion, and our results
are consistent with this idea. As shown in Figure 1, even
though more A3G was incorporated into Vif-competent
HIV (sample 5) compared to Vif-incompetent HIV
(sample 7), the infectivity of Vif-competent HIV was
much higher than the one of Vif –incompetent HIV.
Furthermore, when HAA3G22K, the A3G mutant re-
sistant to Vif-mediated degradation, was used to ensure
equal packaging of A3G into both wild-type and Vif-
deficient viruses, the infectivity of wild-type virus was
10-fold greater than that of Vif-deficient virus. This re-
sult corresponds to the G to A hypermutation rate of
wild-type virus, which was significantly lower than that
of Vif-deficient virus (Figure 3). Ultimately, our results
provide evidence that Vif harbors a backup mechanism
to counteract A3G antiviral function even after A3G is
packaged into the budding virion.
Our lab previously demonstrated that A3G reduces early
and late viral reverse transcription products equally in
the presence or absence of Vif [28]. This ability of A3G
may explain why the viral infectivity of wild-type virus
HXB2N in the presence of HAA3G22K was reduced 10-
fold compared to HXB2N with the pcDNA3.1 control
vector in our system (Figure 3B). In the absence of Vif,
however, A3G would further diminish the integrity of
the viral genome through G to A hypermutations in the
newly synthesized viral cDNA, which would not occur
in a Vif-proficient virus, as shown in Figure 3C. These
data suggest that G to A hypermutations further reduce
the infectivity of Vif-deficient HIV-1. A3G cytidine de-
aminase inactive mutants (such as H257R, C288S and
C291S) inhibit HIV-1 replication through reducing viral
cDNA production [40]. These mutants do not generate
G to A hypermutations [41]. Therefore, we do not ex-
pect Vif will have effects on the antiviral function of the
intraviral form of these mutants.Conclusions
In summary, we used an HIV-1 replication system to
show that HIV-1 Vif has alternate functions for counter-
acting A3G and preserving HIV-1 infectivity. While the
initial function of Vif is to prevent A3G viral incorpor-
ation, this work confirms that Vif also inhibits the G to
A hypermutations catalyzed by A3G. Therefore, any
therapy that hopes to exploit the Vif-A3G axis must take
into account the ability of Vif to overcome A3G in both
the producer cell and the virion. Thus, even though
A3G becomes packaged, Vif is still able to maintain the
fidelity of the virus. A practical strategy for an antiviral
treatment would be not only to increase A3G viral in-
corporation but also to reduce Vif viral packaging.
Methods
Plasmids, antibodies and reagents
The proviral DNA constructs of wild-type HIV-1
(HXB2N) and Vif mutant (HXB2NΔVif) as well as Vif-
cMyc expression vectors were provided by Xiao-Fang Yu
(Johns Hopkins University) [11,16]. HXB2B3 contains
three point mutations in the C-terminal region of Vif as
previously described [42]. The three point mutations were
first introduced into a Vif transfer vector, which contained
the EcoRI- EcoRI DNA fragment of HXB2N, using the
primer GATGGAACAAGCCCCAGGCGACCGCGGGC
CACGCAGGGAGCCACACAATGA and QuikChange
Lightning Multi Site-Directed Mutagenesis Kit (Agilent
Technologies). The DNA fragment containing the three
point mutations was then sub-cloned into the HXB2N
construct to generate HXB2B3. Wild-type A3G and
A3GD128K mutant plasmids were gifts from Yong-Hui
Zheng (Michigan State University). The Vif-resistant
A3G mutant, HA-A3G20K/RΔ2K (hereafter referred to
as HAA3G22K), was previously described [28]. The
monoclonal anti-V5 antibody was purchased from Invi-
trogen. The rabbit anti-Vif antibody, rabbit anti-A3G
antibody [43] and HIV-1 p24 monoclonal antibody [44]
were obtained from NIH-ARRRP.
Cell culture, HIV-1 preparation, HIV-1 purification, DNA
transfection, Western blot analysis and viral infectivity
(MAGI) assay
Human embryonic kidney (HEK) 293T cells and TZM-bl
cells [45] (NIH-ARRRP) were cultured in DMEM con-
taining 10% fetal bovine serum (FBS) in 5% CO2 atmos-
phere at 37°C. The culture supernatant was harvested
48 h post-transfection for the MAGI assay and viral
preparation. HIV-1 virions were prepared from the cell
culture supernatant and separated from cellular debris
by centrifugation at 1,000 × g for 15 min and filtered
through a 0.2 μm pore size membrane. Virus particles
were concentrated by ultracentrifugation at 100,000 × g
for 2 h on a 20% sucrose cushion. Transfections were
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analysis and the MAGI assay were carried out as previ-
ously described [28,46].
Hypermutation assay
293T cells were cotransfected with HIV-1 expression
vectors and A3G expression vectors as indicated. Cul-
ture supernatants were collected 48 h post-transfection
and treated with DNase I (20 U/ml) at 37°C for 1 h.
SupT1 cells (1 × 106) were spin-infected with DNase I-
treated HIV-1 (150 ng p24Gag equivalent) at 2000 × g for
2 h at room temperature. The cells were then washed
with fresh medium and cultured at 37°C, 5% CO2 atmos-
phere. Cells were harvested 12 h post-infection. DNA
was isolated using a DNeasy Blood and Tissue DNA iso-
lation kit (QIAGEN). A 650-bp DNA fragment covering
a portion of nef, U3, and R of HIV-1 was amplified with
Taq DNA polymerase (Invitrogen) using the primers
HIV-1-F (5′-AGGCAGCTGTAGATATTAGCCAC) and
HIV-1-R (5′-GTATGAGGGATCTCTAGCTACCA). The
PCR products were cloned into the TOPO TA-cloning
vector pCR2.1 (Invitrogen). The clones were sequenced,
and the sequencing results were analyzed using the CLC
Main Workbench software. Statistical analysis was per-
formed using the GraphPad Prism 5 software.
A3G cytidine deaminase assay
The FRET-based cytidine deaminase assay was per-
formed based on a modified protocol adapted from a
previously described method [47]. 293T cells were
cotransfected with the indicated HIV-1 expression
vector and the indicated A3G expression vector. At
48 h post-transfection, cells and supernatant were har-
vested, and the virus was concentrated from the
supernatant by ultracentrifugation. NP40 buffer
(0.626% NP40, 10 mM Tris acetate pH 7.5, 50 mM
potassium acetate, 10 mM NaCl) was used to lyse
both cell and viral samples. The cell or viral lysate
(15–20 μl) was mixed with 70 μl master mix contain-
ing 20 pmol Taqman positive control probe (56-FAM/
TTATTATTCCCATTTGATT/-36TAMSp), 1.0 unit
uracil DNA glycosylase (NEB), 50 mM Tris (pH 7.4),
10 mM EDTA, 250 μg/ml RNase A (Qiagen) and
1 μM fluorescence. Cell and viral lysate samples were
incubated at 37°C for 3 h or overnight, respectively.
Thereafter, 4 μl of 4 M NaOH was added to the reac-
tion and incubated for 30 min at 37°C. The reaction
was then neutralized by adding 4 μl of 4 M HCl and
36 μl of 2 M Tris (pH 7.9). The samples were cooled
to 4°C, and fluorescence was measured using a MyiQ
ICycler (Bio-Rad). To measure the background of
each sample, the Taqman negative control probe
(56-FAM/TTATTATTGGGATTTGATT/36-TAMSp) was
used. The cytidine deaminase activity was calculated as afunction of the activity generated from the positive probe
minus the activity generated from the negative probe.
Jurkat A3G and Jurkat HAA3G22K stably expressing cell
lines and HIV-1 replication
To establish stable cell lines, Jurkat cells (1 × 106) were
washed twice with PBS and pulsed with the A3G or
HAA3G22K plasmid (3 μg each) suspended in 10 μl Buf-
fer R using the Invitrogen Neon Transfection System
(pulse voltage 1425 V, pulse width 10 ms and pulse
number 3). After electroporation, the cells were cultured
in RPMI with 10% FBS for two days. G418 (1 mg/ml,
Invitrogen) was added to the culture on day 3 for neo-
mycin resistance selection. Single clones were selected
using the limited dilution method. The APOBEC expres-
sion of the selected cell lines was monitored by Western
blot. HXB2N, HXB2NΔVif and HXB2B3 proviral con-
structs were transfected into 293T cells to produce the
corresponding viruses. Jurkat, Jurkat/A3G and Jurkat/
HAA3G22K cells (6 × 105) were spin-infected with
150 ng of p24 HXB2N, HXB2NΔVif or HXB2B3 virus.
After extensive washes with RPMI, the infected Jurkat
cell lines were cultured at 37°C in a 5% CO2 incubator,
and the supernatant (200 μl) was harvested on days 1, 3,
5 and 7 post-infection. An equal volume of fresh culture
media was added to the culture to maintain a constant
culture volume after each harvest. HIV-1 levels were
assayed using a p24 ELISA kit (AIDS and Cancer Virus
Program, National Cancer Institute, Frederick, MD).
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